CPIX
Cumberland Pharmaceuticals Inc.
Price Chart
Latest Quote
$5.72
+0.11 (+1.96%)
Current Price
| Previous Close | $5.61 |
| Open | $5.70 |
| Day High | $5.73 |
| Day Low | $5.46 |
| Volume | 27,628 |
Stock Information
| Shares Outstanding | 14.98M |
| Total Debt | $10.07M |
| Cash Equivalents | $11.01M |
| Revenue | $41.94M |
| Net Income | $-7.38M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $85.70M |
| EPS (TTM) | $-0.49 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $84.43M |
| Sales | $41.94M |
| Income | $-7.38M |
| Book/sh | $1.44 |
| Cash/sh | $0.73 |
| Employees | 93 |
Financial Ratios
| Quick Ratio | 0.73 |
| Current Ratio | 0.95 |
| Debt/Eq | 47.27 |
Returns & Margins
| ROA | -6.40% |
| ROE | -29.81% |
| Gross Margin | 82.89% |
| Operating Margin | -34.27% |
| Profit Margin | -17.60% |
Ownership
| Insider Ownership | 41.60% |
| Institutional Ownership | 18.65% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 40.86 |
| PEG | 1.67 |
| P/S | 2.04 |
| P/B | 3.96 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $5.74 |
| SMA50 | $4.76 |
| SMA200 | $3.72 |
| RSI | 38.62 |
| ATR | 0.3400 |
| Shares Float | 8.75M |
| Short Float | 4.05% |
| Short Ratio | 1.91 |
| Volatility | 0.10 |
| Rel Volume | 0.44 |
Performance History
| Week | +0.88% |
| Month | +5.73% |
| Quarter | +98.61% |
| 6 Months | +60.22% |
| YTD | +43.72% |
| Year | +5.93% |
| 3 Years | +225.00% |
| 5 Years | +85.11% |
| 10 Years | +24.62% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $5.72 | 40,400 |
| 2026-06-17 | $5.61 | 30,900 |
| 2026-06-16 | $5.67 | 33,800 |
| 2026-06-15 | $5.60 | 26,700 |
| 2026-06-12 | $5.60 | 31,800 |
| 2026-06-11 | $5.67 | 28,600 |
| 2026-06-10 | $5.48 | 80,000 |
| 2026-06-09 | $5.72 | 52,500 |
| 2026-06-08 | $5.86 | 40,100 |
| 2026-06-05 | $5.80 | 62,200 |
| 2026-06-04 | $5.84 | 23,200 |
| 2026-06-03 | $5.61 | 38,300 |
| 2026-06-02 | $5.77 | 106,700 |
| 2026-06-01 | $5.70 | 110,700 |
| 2026-05-29 | $6.15 | 47,900 |
| 2026-05-28 | $5.98 | 504,400 |
| 2026-05-27 | $5.86 | 25,500 |
| 2026-05-26 | $5.77 | 318,200 |
| 2026-05-22 | $5.87 | 118,100 |
| 2026-05-21 | $5.51 | 122,000 |
| 2026-05-20 | $5.53 | 93,500 |
| 2026-05-19 | $5.41 | 114,000 |
About Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
đ° Latest News
Cumberland Expands Global Reach With Vibativ Launch in China
Zacks âĸ 2026-06-02T13:01:00Z
The Zacks Analyst Blog Highlights Alphabet, Apple, Micron Technology, Cumberland Pharmaceuticals and AmeriServ Financial
Zacks âĸ 2026-05-28T10:15:00Z
Top Analyst Reports for Alphabet, Apple & Micron Technology
Zacks âĸ 2026-05-27T20:13:00Z
Cumberland Posts Loss in Q1 Amid $100M Apotex Deal Plan
Zacks âĸ 2026-05-06T14:12:00Z
Cumberland Pharmaceuticals Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-06T12:30:00Z
Cumberland Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-05T23:43:18Z
Cumberland Pharmaceuticals (CPIX) Integrates Commercial Business with Apotex
Insider Monkey âĸ 2026-05-05T12:17:50Z
Broadwind And 2 Promising Penny Stocks For Your Investment Radar
Simply Wall St. âĸ 2026-04-24T18:05:33Z
Cumberland to sell drug portfolio to Apotex for $100m
Hospital Management âĸ 2026-04-24T10:14:46Z
Cumberland Pharmaceuticals jumps on $100M Apotex transaction
InvestorsHub âĸ 2026-04-23T14:52:23Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $5,415,926 | $5,290,926 | $8,398,805 | $8,857,776 |
| Cost Of Revenue | $6,667,207 | $6,585,972 | $6,066,611 | $9,118,521 |
| Total Revenue | $44,521,431 | $37,867,945 | $39,552,507 | $42,010,949 |
| Operating Revenue | $40,396,278 | $36,537,704 | $37,513,492 | $40,681,182 |
| Expenses | ||||
| Interest Expense | $495,990 | $605,508 | $667,861 | $585,995 |
| Total Expenses | $47,313,424 | $44,300,354 | $49,107,168 | $47,715,878 |
| Net Non Operating Interest Income Expense | $-19,242 | $-271,064 | $-381,007 | $-487,590 |
| Interest Expense Non Operating | $495,990 | $605,508 | $667,861 | $585,995 |
| Operating Expense | $40,646,217 | $37,714,382 | $43,040,557 | $38,597,357 |
| Selling And Marketing Expense | $19,098,153 | $17,023,023 | $18,451,765 | $16,660,945 |
| General And Administrative Expense | $11,946,909 | $11,126,901 | $10,651,915 | $10,180,120 |
| Other Income Expense | - | $237,089 | $3,650,671 | $611,330 |
| Other Non Operating Income Expenses | - | - | $2,828,871 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-2,836,128 | $-6,479,770 | $-6,279,320 | $-5,570,241 |
| Net Interest Income | $-19,242 | $-271,064 | $-381,007 | $-487,590 |
| Interest Income | $476,748 | $334,444 | $286,854 | $98,405 |
| Normalized Income | $-2,836,128 | $-6,716,053 | $-6,928,542 | $-6,053,192 |
| Net Income From Continuing And Discontinued Operation | $-2,836,128 | $-6,479,770 | $-6,279,320 | $-5,570,241 |
| Total Operating Income As Reported | $-2,791,993 | $-6,432,409 | $-9,554,661 | $-5,704,929 |
| Net Income Common Stockholders | $-2,836,128 | $-6,479,770 | $-6,279,320 | $-5,570,241 |
| Net Income | $-2,836,128 | $-6,479,770 | $-6,279,320 | $-5,570,241 |
| Net Income Including Noncontrolling Interests | $-2,864,711 | $-6,443,715 | $-6,330,766 | $-5,650,039 |
| Net Income Continuous Operations | $-2,864,711 | $-6,443,715 | $-6,330,766 | $-5,650,039 |
| Earnings From Equity Interest Net Of Tax | $-13,220 | $0 | - | - |
| Pretax Income | $-2,811,235 | $-6,466,384 | $-6,284,997 | $-5,581,189 |
| Special Income Charges | $0 | $237,089 | $821,800 | $611,330 |
| Interest Income Non Operating | $476,748 | $334,444 | $286,854 | $98,405 |
| Operating Income | $-2,791,993 | $-6,432,409 | $-9,554,661 | $-5,704,929 |
| Depreciation Amortization Depletion Income Statement | $4,034,657 | $4,748,252 | $8,102,648 | $5,067,368 |
| Depreciation And Amortization In Income Statement | $4,034,657 | $4,748,252 | $8,102,648 | $5,067,368 |
| Amortization Of Intangibles Income Statement | $4,034,657 | $4,748,252 | $8,102,648 | $5,067,368 |
| Gross Profit | $37,854,224 | $31,281,973 | $33,485,896 | $32,892,428 |
| Net Income Discontinuous Operations | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-0.19 | $-0.46 | $-0.44 | $-0.38 |
| Basic EPS | $-0.19 | $-0.46 | $-0.44 | $-0.38 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $806 | $172,578 | $128,379 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $2,970,693 | $-54,667 | $1,663,712 | $-278,411 |
| Total Unusual Items | $0 | $237,089 | $821,800 | $611,330 |
| Total Unusual Items Excluding Goodwill | $0 | $237,089 | $821,800 | $611,330 |
| Reconciled Depreciation | $5,285,938 | $6,043,298 | $5,770,454 | $5,328,113 |
| EBITDA (Bullshit earnings) | $2,970,693 | $182,422 | $2,485,512 | $332,919 |
| EBIT | $-2,315,245 | $-5,860,876 | $-5,617,136 | $-4,995,194 |
| Diluted Average Shares | $14,854,619 | $14,060,272 | $14,298,774 | $14,563,592 |
| Basic Average Shares | $14,854,619 | $14,060,272 | $14,298,774 | $14,563,592 |
| Diluted NI Availto Com Stockholders | $-2,836,128 | $-6,479,770 | $-6,279,320 | $-5,570,241 |
| Minority Interests | $28,583 | $-36,055 | $51,446 | $79,798 |
| Tax Provision | $40,256 | $-22,669 | $45,769 | $68,850 |
| Amortization | $4,034,657 | $4,748,252 | $8,102,648 | $5,067,368 |
| Research And Development | $5,566,498 | $4,816,206 | $5,834,229 | $6,688,924 |
| Selling General And Administration | $31,045,062 | $28,149,924 | $29,103,680 | $26,841,065 |
| Other Gand A | $11,946,909 | $11,126,901 | $10,651,915 | $10,180,120 |
| Other Special Charges | - | $-237,089 | $-821,800 | $-611,330 |
Fetched: 2026-06-12
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $9,938,401 | $3,966,045 | $6,081,523 | $4,761,454 |
| Total Assets | $76,823,992 | $75,583,410 | $81,776,075 | $92,925,158 |
| Total Non Current Assets | $39,763,725 | $39,131,252 | $46,061,665 | $47,054,948 |
| Other Non Current Assets | $12,226,468 | $13,789,515 | $15,497,450 | $10,047,828 |
| Goodwill And Other Intangible Assets | $14,941,921 | $18,887,449 | $23,521,918 | $31,504,678 |
| Other Intangible Assets | $14,027,921 | $17,973,449 | $22,607,918 | $30,590,678 |
| Current Assets | $37,060,267 | $36,452,158 | $35,714,410 | $45,870,210 |
| Other Current Assets | $2,445,276 | $2,786,513 | $3,025,248 | $3,084,978 |
| Inventory | $6,225,518 | $3,999,995 | $4,609,362 | $9,863,581 |
| Receivables | $16,944,780 | $11,701,466 | $9,758,176 | $13,163,681 |
| Accounts Receivable | $16,944,780 | $11,701,466 | $9,758,176 | $13,163,681 |
| Allowance For Doubtful Accounts Receivable | $-9,000,000 | $-1,100,000 | $-600,000 | $-600,000 |
| Gross Accounts Receivable | $25,944,780 | $12,801,466 | $10,358,176 | $13,763,681 |
| Cash Cash Equivalents And Short Term Investments | $11,444,693 | $17,964,184 | $18,321,624 | $19,757,970 |
| Cash And Cash Equivalents | $11,444,693 | $17,964,184 | $18,321,624 | $19,757,970 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $10,180,472 | $20,572,417 | $18,428,483 | $20,959,211 |
| Long Term Debt And Capital Lease Obligation | $9,712,698 | $15,115,909 | $18,080,391 | $20,786,301 |
| Long Term Debt | $5,240,733 | $10,176,170 | $12,784,144 | $16,200,000 |
| Current Debt And Capital Lease Obligation | $467,774 | $5,456,508 | $348,092 | $172,910 |
| Current Debt | - | $5,100,000 | - | - |
| Other Current Borrowings | - | $5,100,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $52,279,770 | $53,037,433 | $52,516,206 | $56,951,152 |
| Total Non Current Liabilities Net Minority Interest | $15,534,851 | $21,415,704 | $24,533,957 | $28,371,320 |
| Other Non Current Liabilities | $250,000 | $250,000 | $274,000 | $131,000 |
| Non Current Deferred Liabilities | $3,376,875 | $3,172,483 | $2,894,894 | $2,522,506 |
| Current Liabilities | $36,744,919 | $31,621,729 | $27,982,249 | $28,579,832 |
| Other Current Liabilities | $13,420,292 | $8,769,725 | $9,369,028 | $11,515,868 |
| Current Deferred Liabilities | $25,000 | $207,059 | $220,402 | $614,551 |
| Payables And Accrued Expenses | $21,352,896 | $15,987,647 | $16,846,895 | $14,835,644 |
| Payables | $18,567,546 | $13,914,266 | $14,037,629 | $10,819,011 |
| Accounts Payable | $18,567,546 | $13,914,266 | $14,037,629 | $10,819,011 |
| Equity | ||||
| Common Stock Equity | $24,880,322 | $22,853,494 | $29,603,441 | $36,266,132 |
| Total Equity Gross Minority Interest | $24,544,222 | $22,545,977 | $29,259,869 | $35,974,006 |
| Stockholders Equity | $24,880,322 | $22,853,494 | $29,603,441 | $36,266,132 |
| Retained Earnings | $-26,804,059 | $-23,967,931 | $-17,488,161 | $-11,208,841 |
| Other | ||||
| Ordinary Shares Number | $14,956,627 | $13,952,624 | $14,121,833 | $14,366,316 |
| Share Issued | $14,956,627 | $13,952,624 | $14,121,833 | $14,366,316 |
| Tangible Book Value | $9,938,401 | $3,966,045 | $6,081,523 | $4,761,454 |
| Invested Capital | $30,121,055 | $38,129,664 | $42,387,585 | $52,466,132 |
| Working Capital | $315,348 | $4,830,429 | $7,732,161 | $17,290,378 |
| Capital Lease Obligations | $4,939,739 | $5,296,247 | $5,644,339 | $4,759,211 |
| Total Capitalization | $30,121,055 | $33,029,664 | $42,387,585 | $52,466,132 |
| Minority Interest | $-336,100 | $-307,517 | $-343,572 | $-292,126 |
| Capital Stock | $51,684,381 | $46,821,425 | $47,091,602 | $47,474,973 |
| Common Stock | $51,684,381 | $46,821,425 | $47,091,602 | $47,474,973 |
| Non Current Accrued Expenses | $2,195,278 | $2,877,312 | $3,284,672 | $4,931,513 |
| Long Term Capital Lease Obligation | $4,471,965 | $4,939,739 | $5,296,247 | $4,586,301 |
| Current Capital Lease Obligation | $467,774 | $356,508 | $348,092 | $172,910 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,478,957 | $1,200,790 | $1,197,832 | $1,440,859 |
| Current Accrued Expenses | $2,785,350 | $2,073,381 | $2,809,266 | $4,016,633 |
| Investments And Advances | $3,986,780 | $0 | - | - |
| Goodwill | $914,000 | $914,000 | $914,000 | $914,000 |
| Net PPE | $8,608,556 | $6,454,288 | $7,042,297 | $5,502,442 |
| Accumulated Depreciation | $-2,502,387 | $-2,391,843 | $-2,238,073 | $-2,085,185 |
| Gross PPE | $11,110,943 | $8,846,131 | $9,280,370 | $7,587,627 |
| Leases | $9,185,495 | $7,001,997 | $7,475,368 | $6,006,152 |
| Machinery Furniture Equipment | $1,925,448 | $1,844,134 | $1,805,002 | $1,581,475 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-9,253,090 | $-11,005,499 | $-12,804,529 | $-7,527,167 |
| Finished Goods | $5,646,315 | $2,897,359 | $4,645,098 | $4,322,167 |
| Raw Materials | $9,832,293 | $11,982,045 | $12,619,092 | $12,899,659 |
| Other Inventories | - | $126,090 | $149,701 | $168,922 |
| Line Of Credit | - | - | - | - |
| Buildings And Improvements | - | - | - | - |
Fetched: 2026-06-12
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $4,750,217 | $-791,900 | $5,640,770 | $6,379,586 |
| Operating Activities | ||||
| Operating Cash Flow | $4,932,522 | $-612,186 | $6,093,821 | $8,453,396 |
| Cash Flow From Continuing Operating Activities | $4,932,521 | $-612,186 | $6,093,821 | $8,453,396 |
| Operating Gains Losses | $13,220 | $2,691 | $20,256 | - |
| Cash From Discontinued Operating Activities | - | - | - | $0 |
| Investing Activities | ||||
| Capital Expenditure | $-182,305 | $-179,714 | $-453,051 | $-2,073,810 |
| Investing Cash Flow | $-4,706,497 | $57,842 | $-105,695 | $-13,674,456 |
| Cash Flow From Continuing Investing Activities | $-4,706,497 | $57,842 | $-105,695 | $-13,674,456 |
| Net Other Investing Changes | $-47,000 | $237,556 | $347,356 | $1,899,354 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-263,478 | $-579,049 | $-740,533 | $-1,053,042 |
| Issuance Of Capital Stock | $5,266,334 | $0 | - | - |
| Financing Cash Flow | $-6,745,516 | $196,904 | $-7,424,472 | $-2,061,786 |
| Cash Flow From Continuing Financing Activities | $-6,745,516 | $196,904 | $-7,424,472 | $-2,061,786 |
| Net Other Financing Charges | $-1,712,935 | $-1,716,073 | $-3,268,083 | $-2,208,744 |
| Net Common Stock Issuance | $5,002,856 | $-579,049 | $-740,533 | $-1,053,042 |
| Common Stock Issuance | $5,266,334 | $0 | - | - |
| Other | ||||
| Repayment Of Debt | $-10,035,437 | $-35,996,894 | $-34,890,856 | $-51,700,000 |
| Issuance Of Debt | $0 | $38,488,920 | $31,475,000 | $52,900,000 |
| Interest Paid Supplemental Data | $441,677 | $569,230 | $647,137 | $523,161 |
| End Cash Position | $11,444,693 | $17,964,184 | $18,321,624 | $19,757,970 |
| Beginning Cash Position | $17,964,184 | $18,321,624 | $19,757,970 | $27,040,816 |
| Changes In Cash | $-6,519,491 | $-357,440 | $-1,436,346 | $-7,282,846 |
| Common Stock Payments | $-263,478 | $-579,049 | $-740,533 | $-1,053,042 |
| Net Issuance Payments Of Debt | $-10,035,437 | $2,492,026 | $-3,415,856 | $1,200,000 |
| Net Long Term Debt Issuance | $-10,035,437 | $2,492,026 | $-3,415,856 | $1,200,000 |
| Long Term Debt Payments | $-10,035,437 | $-35,996,894 | $-34,890,856 | $-51,700,000 |
| Long Term Debt Issuance | $0 | $38,488,920 | $31,475,000 | $52,900,000 |
| Net Investment Purchase And Sale | $-4,477,192 | $0 | - | $0 |
| Purchase Of Investment | $-4,477,192 | $0 | - | $0 |
| Net Intangibles Purchase And Sale | $-84,402 | $-113,253 | $-171,783 | $-1,971,662 |
| Purchase Of Intangibles | $-84,402 | $-113,253 | $-171,783 | $-1,971,662 |
| Net PPE Purchase And Sale | $-97,903 | $-66,461 | $-281,268 | $-102,148 |
| Purchase Of PPE | $-97,903 | $-66,461 | $-281,268 | $-102,148 |
| Change In Working Capital | $2,162,927 | $1,293,178 | $4,634,848 | $10,440,433 |
| Change In Other Current Liabilities | $-1,313,742 | $1,630,318 | $-2,536,816 | $419,659 |
| Change In Other Current Assets | $-231,829 | $189,112 | $65,684 | $689,260 |
| Change In Payables And Accrued Expense | $6,709,196 | $-991,359 | $3,724,174 | $14,536,076 |
| Change In Payable | $6,709,196 | $-991,359 | $3,724,174 | $14,536,076 |
| Change In Account Payable | $6,709,196 | $-991,359 | $3,724,174 | $14,536,076 |
| Change In Inventory | $2,242,616 | $2,408,397 | $-23,143 | $911,078 |
| Change In Receivables | $-5,243,314 | $-1,943,290 | $3,404,949 | $-6,115,640 |
| Changes In Account Receivables | $-5,243,314 | $-1,943,290 | $3,404,949 | $-6,115,640 |
| Other Non Cash Items | $-73,172 | $-1,809,533 | $-1,709,853 | $-2,112,614 |
| Stock Based Compensation | $408,320 | $301,895 | $365,040 | $447,503 |
| Depreciation Amortization Depletion | $5,285,938 | $6,043,298 | $5,770,454 | $5,328,113 |
| Depreciation And Amortization | $5,285,938 | $6,043,298 | $5,770,454 | $5,328,113 |
| Amortization Cash Flow | $4,034,657 | $4,748,252 | - | $5,067,368 |
| Amortization Of Intangibles | $4,034,657 | $4,748,252 | - | $5,067,368 |
| Depreciation | $1,251,281 | $1,295,046 | $5,770,454 | $5,328,113 |
| Gain Loss On Investment Securities | $13,220 | - | - | - |
| Net Income From Continuing Operations | $-2,864,711 | $-6,443,715 | $-6,330,766 | $-5,650,039 |
| Income Tax Paid Supplemental Data | - | $15,000 | $108,823 | $3,300 |
| Asset Impairment Charge | - | $0 | $3,343,842 | $0 |
| Net Business Purchase And Sale | - | - | $0 | $-13,500,000 |
| Purchase Of Business | - | - | $0 | $-13,500,000 |
| Deferred Tax | - | - | - | $0 |
| Deferred Income Tax | - | - | - | $0 |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Payments | - | - | - | - |
| Short Term Debt Issuance | - | - | - | - |
| Sale Of Investment | - | - | - | - |
Fetched: 2026-06-12